NVO News & Events

Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study.

Moderately bullish activity in Novo Nordisk (NVO), with shares up 72c, or 1.51%, near $48.66. Options volume roughly in line with average with 56k contracts traded and calls leading puts for a put/call ratio of 0.72, compared to a typical level near 0.62. Implied volatility (IV30) is higher by 1.1 points near 37.78,in the bottom quartile of the past year, suggesting an expected daily move of $1.16. Put-call skew flattened, suggesting a modestly bullish tone.